Stocks · News reference

NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding

Jul 24, 2026, 3:08 PMAkanksha Bakshi

NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 24, 2026, 3:08 PM
Checked: Jul 24, 2026, 3:08 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 1, 2026, 1:04 PMBenzinga Newsdesk
Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic Cancer
NVCR
SEC EDGAROct 1, 2026, 1:00 PMSEC EDGAR
8-K filing — NovoCure Ltd (NVCR)
Filed: 2026-10-01 AccNo: 0001645113-26-000071 Size: 163 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NVCR
BenzingaSep 1, 2026, 11:05 AMBenzinga Newsdesk
Novocure Reported Unauthorized Systems Access In Mid-August 2026, Exposing Internal Patient ID Numbers For Over 1,400 U.S. Records; No Medical Device Access Obtained, Operations, Systems Fully Functional
NVCR